37
C. Noel Bairey Merz MD, FACC, FAHA, FESC Professor and Endowed Chair Director, Barbra Streisand Women’s Heart Cetner Director, Preventive Cardiac Center Cedars-Sinai Smidt Heart Institute Los Angeles, California, USA [email protected] Ischemic Heart Disease in Women: Monet vs Manet (why women have more adverse outcomes)

Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

  • Upload
    others

  • View
    5

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

C Noel Bairey Merz MD FACC FAHA FESCProfessor and Endowed ChairDirector Barbra Streisand Womenrsquos Heart CetnerDirector Preventive Cardiac CenterCedars-Sinai Smidt Heart InstituteLos Angeles California USAmerzcshsorg

Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)

2

Financial conflicts of interests

bull The following relationships exist related to this presentation (paid to Cedars-Sinai Medical Center)

bull Grant support NHLBI Louis B Mayer Foundation NIH-CTSI CMDRP-DoD NIH-Caladrius California Institute for Precision Medicine (CIAPM) Sanofi-Vascular

bull Consulting Medscape Sanofi-Vascular NIH CSR and NIH ORWHAB iRhythm

bull Honorarium Abbott Diagnostics bull Stocks Nonepaid to CSMC

Monet or Manet

Monet or Manet

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

New femalemajority Yentl and

Yentl Syndrome

WISENHLBIAHABegin

1984-1996 12 years to recognize take action

1615PC Bairey-MerzSlide

8

Bugiardini and Bairey Merz JAMA 2005293477-84

Paradox Women have a two-fold increase in ldquonormalrdquo Coronary arteries in the setting of ACS NSTEMI and STEMI

9

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Monet vs ManetMore womendie

More men receive treatment

Bairey Merz EHJ 2011

GuidelineImplementation ACS and the Sex Survival Gap

Novak et al Am J Medicine 2008121602

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrows(RED)

Novak et al Am J Medicine 2008121602

+

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrow (RED)

Persistent sex gap (BLUE)suggests more workstill neededto understand sex-specific pathophysiologyto improve outcomesfor women and men

Novak et al Am J Medicine 2008121602

+

14

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Anderson RD et al Circulation 2007115823-826

Prevalence of normal or non-obstructive coronary arteriescommon in women

Normal Coronaries

22

1V Non-Obstructive

CAD14

2V Non-Obstructive

CAD8

3V Non-Obstructive

CAD3

1V Obstructive CAD23

2V Obstructive CAD14

3VLM Obstructive

CAD16

VA CART 37674 male patients ndash47 non-obstructive or normal coronary arteries

Now common in men

17Crea Filippo Paolo G Camici and Cathleen Noel Bairey Merz Coronary microvascular dysfunction an update European heart journal (2013) eht513

Mechanisms of Myocardial Ischemia (including INOCA)

Coronary Vascular Resistance

bullEpicardial arteries normally

contribute lt10 of the

coronary vascular resistance

ndashhemodynamic significance when

gt70 of the lumen is obstructed

bullCoronary microvasculature

is responsible for gt70 of

the coronary resistance

under physiological

circumstances Gould KL et al Am J Cardiol 19743387ndash94 Camici P et al Heart Lung and Circ 20091819-27

wwwvhlabumnedu

Coronary Microvascular Dysfunction

Crea F et al Nature Reviews Cardiology 20151248ndash62

20

DES in Stable Angina ORBITA Trial

21

Change from Baseline PCI Sham P ValueExercise time (sec) 284 118 0200Peak oxygen uptake (mlmin) -20 109 0741SAQ Physical Limitation 74 50 0420SAQ Angina Frequency 140 96 0260SAQ Angina Stability -42 -51 0851Quality of Life 003 003 0994Duke Treadmill Score 122 010 0104Complete Freedom from Angina 495 315 lt005

Compared with placebo PCI improved stress echo by 107 segment units (plt000001) with larger improvements in stress echo with lower levels of FFR and iFR (pinteraction lt000001)

Al-Lamee R et al Lancet 2018 391 31ndash40

22

Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis

80

23

Chan

ge in

PCr

ATP

dur

ing

stre

ss p

erce

nt

-50

-40

-30

-20

-10

0

10

20

30

gt70 StenosisWomen with Chest Pain

but normal Angio

ReferencePopulation

p lt 0025compared to normals

2 sd

Myocardial ischemia is frequent in subjects with signs and symptoms but no obstructive coronary diseaseThese are not ldquofalse positiverdquo stress tests

Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects

Buchal et al NEJM 2001

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 2: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

2

Financial conflicts of interests

bull The following relationships exist related to this presentation (paid to Cedars-Sinai Medical Center)

bull Grant support NHLBI Louis B Mayer Foundation NIH-CTSI CMDRP-DoD NIH-Caladrius California Institute for Precision Medicine (CIAPM) Sanofi-Vascular

bull Consulting Medscape Sanofi-Vascular NIH CSR and NIH ORWHAB iRhythm

bull Honorarium Abbott Diagnostics bull Stocks Nonepaid to CSMC

Monet or Manet

Monet or Manet

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

New femalemajority Yentl and

Yentl Syndrome

WISENHLBIAHABegin

1984-1996 12 years to recognize take action

1615PC Bairey-MerzSlide

8

Bugiardini and Bairey Merz JAMA 2005293477-84

Paradox Women have a two-fold increase in ldquonormalrdquo Coronary arteries in the setting of ACS NSTEMI and STEMI

9

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Monet vs ManetMore womendie

More men receive treatment

Bairey Merz EHJ 2011

GuidelineImplementation ACS and the Sex Survival Gap

Novak et al Am J Medicine 2008121602

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrows(RED)

Novak et al Am J Medicine 2008121602

+

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrow (RED)

Persistent sex gap (BLUE)suggests more workstill neededto understand sex-specific pathophysiologyto improve outcomesfor women and men

Novak et al Am J Medicine 2008121602

+

14

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Anderson RD et al Circulation 2007115823-826

Prevalence of normal or non-obstructive coronary arteriescommon in women

Normal Coronaries

22

1V Non-Obstructive

CAD14

2V Non-Obstructive

CAD8

3V Non-Obstructive

CAD3

1V Obstructive CAD23

2V Obstructive CAD14

3VLM Obstructive

CAD16

VA CART 37674 male patients ndash47 non-obstructive or normal coronary arteries

Now common in men

17Crea Filippo Paolo G Camici and Cathleen Noel Bairey Merz Coronary microvascular dysfunction an update European heart journal (2013) eht513

Mechanisms of Myocardial Ischemia (including INOCA)

Coronary Vascular Resistance

bullEpicardial arteries normally

contribute lt10 of the

coronary vascular resistance

ndashhemodynamic significance when

gt70 of the lumen is obstructed

bullCoronary microvasculature

is responsible for gt70 of

the coronary resistance

under physiological

circumstances Gould KL et al Am J Cardiol 19743387ndash94 Camici P et al Heart Lung and Circ 20091819-27

wwwvhlabumnedu

Coronary Microvascular Dysfunction

Crea F et al Nature Reviews Cardiology 20151248ndash62

20

DES in Stable Angina ORBITA Trial

21

Change from Baseline PCI Sham P ValueExercise time (sec) 284 118 0200Peak oxygen uptake (mlmin) -20 109 0741SAQ Physical Limitation 74 50 0420SAQ Angina Frequency 140 96 0260SAQ Angina Stability -42 -51 0851Quality of Life 003 003 0994Duke Treadmill Score 122 010 0104Complete Freedom from Angina 495 315 lt005

Compared with placebo PCI improved stress echo by 107 segment units (plt000001) with larger improvements in stress echo with lower levels of FFR and iFR (pinteraction lt000001)

Al-Lamee R et al Lancet 2018 391 31ndash40

22

Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis

80

23

Chan

ge in

PCr

ATP

dur

ing

stre

ss p

erce

nt

-50

-40

-30

-20

-10

0

10

20

30

gt70 StenosisWomen with Chest Pain

but normal Angio

ReferencePopulation

p lt 0025compared to normals

2 sd

Myocardial ischemia is frequent in subjects with signs and symptoms but no obstructive coronary diseaseThese are not ldquofalse positiverdquo stress tests

Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects

Buchal et al NEJM 2001

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 3: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

Monet or Manet

Monet or Manet

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

New femalemajority Yentl and

Yentl Syndrome

WISENHLBIAHABegin

1984-1996 12 years to recognize take action

1615PC Bairey-MerzSlide

8

Bugiardini and Bairey Merz JAMA 2005293477-84

Paradox Women have a two-fold increase in ldquonormalrdquo Coronary arteries in the setting of ACS NSTEMI and STEMI

9

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Monet vs ManetMore womendie

More men receive treatment

Bairey Merz EHJ 2011

GuidelineImplementation ACS and the Sex Survival Gap

Novak et al Am J Medicine 2008121602

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrows(RED)

Novak et al Am J Medicine 2008121602

+

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrow (RED)

Persistent sex gap (BLUE)suggests more workstill neededto understand sex-specific pathophysiologyto improve outcomesfor women and men

Novak et al Am J Medicine 2008121602

+

14

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Anderson RD et al Circulation 2007115823-826

Prevalence of normal or non-obstructive coronary arteriescommon in women

Normal Coronaries

22

1V Non-Obstructive

CAD14

2V Non-Obstructive

CAD8

3V Non-Obstructive

CAD3

1V Obstructive CAD23

2V Obstructive CAD14

3VLM Obstructive

CAD16

VA CART 37674 male patients ndash47 non-obstructive or normal coronary arteries

Now common in men

17Crea Filippo Paolo G Camici and Cathleen Noel Bairey Merz Coronary microvascular dysfunction an update European heart journal (2013) eht513

Mechanisms of Myocardial Ischemia (including INOCA)

Coronary Vascular Resistance

bullEpicardial arteries normally

contribute lt10 of the

coronary vascular resistance

ndashhemodynamic significance when

gt70 of the lumen is obstructed

bullCoronary microvasculature

is responsible for gt70 of

the coronary resistance

under physiological

circumstances Gould KL et al Am J Cardiol 19743387ndash94 Camici P et al Heart Lung and Circ 20091819-27

wwwvhlabumnedu

Coronary Microvascular Dysfunction

Crea F et al Nature Reviews Cardiology 20151248ndash62

20

DES in Stable Angina ORBITA Trial

21

Change from Baseline PCI Sham P ValueExercise time (sec) 284 118 0200Peak oxygen uptake (mlmin) -20 109 0741SAQ Physical Limitation 74 50 0420SAQ Angina Frequency 140 96 0260SAQ Angina Stability -42 -51 0851Quality of Life 003 003 0994Duke Treadmill Score 122 010 0104Complete Freedom from Angina 495 315 lt005

Compared with placebo PCI improved stress echo by 107 segment units (plt000001) with larger improvements in stress echo with lower levels of FFR and iFR (pinteraction lt000001)

Al-Lamee R et al Lancet 2018 391 31ndash40

22

Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis

80

23

Chan

ge in

PCr

ATP

dur

ing

stre

ss p

erce

nt

-50

-40

-30

-20

-10

0

10

20

30

gt70 StenosisWomen with Chest Pain

but normal Angio

ReferencePopulation

p lt 0025compared to normals

2 sd

Myocardial ischemia is frequent in subjects with signs and symptoms but no obstructive coronary diseaseThese are not ldquofalse positiverdquo stress tests

Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects

Buchal et al NEJM 2001

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 4: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

Monet or Manet

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

New femalemajority Yentl and

Yentl Syndrome

WISENHLBIAHABegin

1984-1996 12 years to recognize take action

1615PC Bairey-MerzSlide

8

Bugiardini and Bairey Merz JAMA 2005293477-84

Paradox Women have a two-fold increase in ldquonormalrdquo Coronary arteries in the setting of ACS NSTEMI and STEMI

9

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Monet vs ManetMore womendie

More men receive treatment

Bairey Merz EHJ 2011

GuidelineImplementation ACS and the Sex Survival Gap

Novak et al Am J Medicine 2008121602

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrows(RED)

Novak et al Am J Medicine 2008121602

+

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrow (RED)

Persistent sex gap (BLUE)suggests more workstill neededto understand sex-specific pathophysiologyto improve outcomesfor women and men

Novak et al Am J Medicine 2008121602

+

14

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Anderson RD et al Circulation 2007115823-826

Prevalence of normal or non-obstructive coronary arteriescommon in women

Normal Coronaries

22

1V Non-Obstructive

CAD14

2V Non-Obstructive

CAD8

3V Non-Obstructive

CAD3

1V Obstructive CAD23

2V Obstructive CAD14

3VLM Obstructive

CAD16

VA CART 37674 male patients ndash47 non-obstructive or normal coronary arteries

Now common in men

17Crea Filippo Paolo G Camici and Cathleen Noel Bairey Merz Coronary microvascular dysfunction an update European heart journal (2013) eht513

Mechanisms of Myocardial Ischemia (including INOCA)

Coronary Vascular Resistance

bullEpicardial arteries normally

contribute lt10 of the

coronary vascular resistance

ndashhemodynamic significance when

gt70 of the lumen is obstructed

bullCoronary microvasculature

is responsible for gt70 of

the coronary resistance

under physiological

circumstances Gould KL et al Am J Cardiol 19743387ndash94 Camici P et al Heart Lung and Circ 20091819-27

wwwvhlabumnedu

Coronary Microvascular Dysfunction

Crea F et al Nature Reviews Cardiology 20151248ndash62

20

DES in Stable Angina ORBITA Trial

21

Change from Baseline PCI Sham P ValueExercise time (sec) 284 118 0200Peak oxygen uptake (mlmin) -20 109 0741SAQ Physical Limitation 74 50 0420SAQ Angina Frequency 140 96 0260SAQ Angina Stability -42 -51 0851Quality of Life 003 003 0994Duke Treadmill Score 122 010 0104Complete Freedom from Angina 495 315 lt005

Compared with placebo PCI improved stress echo by 107 segment units (plt000001) with larger improvements in stress echo with lower levels of FFR and iFR (pinteraction lt000001)

Al-Lamee R et al Lancet 2018 391 31ndash40

22

Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis

80

23

Chan

ge in

PCr

ATP

dur

ing

stre

ss p

erce

nt

-50

-40

-30

-20

-10

0

10

20

30

gt70 StenosisWomen with Chest Pain

but normal Angio

ReferencePopulation

p lt 0025compared to normals

2 sd

Myocardial ischemia is frequent in subjects with signs and symptoms but no obstructive coronary diseaseThese are not ldquofalse positiverdquo stress tests

Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects

Buchal et al NEJM 2001

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 5: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

New femalemajority Yentl and

Yentl Syndrome

WISENHLBIAHABegin

1984-1996 12 years to recognize take action

1615PC Bairey-MerzSlide

8

Bugiardini and Bairey Merz JAMA 2005293477-84

Paradox Women have a two-fold increase in ldquonormalrdquo Coronary arteries in the setting of ACS NSTEMI and STEMI

9

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Monet vs ManetMore womendie

More men receive treatment

Bairey Merz EHJ 2011

GuidelineImplementation ACS and the Sex Survival Gap

Novak et al Am J Medicine 2008121602

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrows(RED)

Novak et al Am J Medicine 2008121602

+

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrow (RED)

Persistent sex gap (BLUE)suggests more workstill neededto understand sex-specific pathophysiologyto improve outcomesfor women and men

Novak et al Am J Medicine 2008121602

+

14

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Anderson RD et al Circulation 2007115823-826

Prevalence of normal or non-obstructive coronary arteriescommon in women

Normal Coronaries

22

1V Non-Obstructive

CAD14

2V Non-Obstructive

CAD8

3V Non-Obstructive

CAD3

1V Obstructive CAD23

2V Obstructive CAD14

3VLM Obstructive

CAD16

VA CART 37674 male patients ndash47 non-obstructive or normal coronary arteries

Now common in men

17Crea Filippo Paolo G Camici and Cathleen Noel Bairey Merz Coronary microvascular dysfunction an update European heart journal (2013) eht513

Mechanisms of Myocardial Ischemia (including INOCA)

Coronary Vascular Resistance

bullEpicardial arteries normally

contribute lt10 of the

coronary vascular resistance

ndashhemodynamic significance when

gt70 of the lumen is obstructed

bullCoronary microvasculature

is responsible for gt70 of

the coronary resistance

under physiological

circumstances Gould KL et al Am J Cardiol 19743387ndash94 Camici P et al Heart Lung and Circ 20091819-27

wwwvhlabumnedu

Coronary Microvascular Dysfunction

Crea F et al Nature Reviews Cardiology 20151248ndash62

20

DES in Stable Angina ORBITA Trial

21

Change from Baseline PCI Sham P ValueExercise time (sec) 284 118 0200Peak oxygen uptake (mlmin) -20 109 0741SAQ Physical Limitation 74 50 0420SAQ Angina Frequency 140 96 0260SAQ Angina Stability -42 -51 0851Quality of Life 003 003 0994Duke Treadmill Score 122 010 0104Complete Freedom from Angina 495 315 lt005

Compared with placebo PCI improved stress echo by 107 segment units (plt000001) with larger improvements in stress echo with lower levels of FFR and iFR (pinteraction lt000001)

Al-Lamee R et al Lancet 2018 391 31ndash40

22

Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis

80

23

Chan

ge in

PCr

ATP

dur

ing

stre

ss p

erce

nt

-50

-40

-30

-20

-10

0

10

20

30

gt70 StenosisWomen with Chest Pain

but normal Angio

ReferencePopulation

p lt 0025compared to normals

2 sd

Myocardial ischemia is frequent in subjects with signs and symptoms but no obstructive coronary diseaseThese are not ldquofalse positiverdquo stress tests

Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects

Buchal et al NEJM 2001

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 6: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

New femalemajority Yentl and

Yentl Syndrome

WISENHLBIAHABegin

1984-1996 12 years to recognize take action

1615PC Bairey-MerzSlide

8

Bugiardini and Bairey Merz JAMA 2005293477-84

Paradox Women have a two-fold increase in ldquonormalrdquo Coronary arteries in the setting of ACS NSTEMI and STEMI

9

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Monet vs ManetMore womendie

More men receive treatment

Bairey Merz EHJ 2011

GuidelineImplementation ACS and the Sex Survival Gap

Novak et al Am J Medicine 2008121602

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrows(RED)

Novak et al Am J Medicine 2008121602

+

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrow (RED)

Persistent sex gap (BLUE)suggests more workstill neededto understand sex-specific pathophysiologyto improve outcomesfor women and men

Novak et al Am J Medicine 2008121602

+

14

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Anderson RD et al Circulation 2007115823-826

Prevalence of normal or non-obstructive coronary arteriescommon in women

Normal Coronaries

22

1V Non-Obstructive

CAD14

2V Non-Obstructive

CAD8

3V Non-Obstructive

CAD3

1V Obstructive CAD23

2V Obstructive CAD14

3VLM Obstructive

CAD16

VA CART 37674 male patients ndash47 non-obstructive or normal coronary arteries

Now common in men

17Crea Filippo Paolo G Camici and Cathleen Noel Bairey Merz Coronary microvascular dysfunction an update European heart journal (2013) eht513

Mechanisms of Myocardial Ischemia (including INOCA)

Coronary Vascular Resistance

bullEpicardial arteries normally

contribute lt10 of the

coronary vascular resistance

ndashhemodynamic significance when

gt70 of the lumen is obstructed

bullCoronary microvasculature

is responsible for gt70 of

the coronary resistance

under physiological

circumstances Gould KL et al Am J Cardiol 19743387ndash94 Camici P et al Heart Lung and Circ 20091819-27

wwwvhlabumnedu

Coronary Microvascular Dysfunction

Crea F et al Nature Reviews Cardiology 20151248ndash62

20

DES in Stable Angina ORBITA Trial

21

Change from Baseline PCI Sham P ValueExercise time (sec) 284 118 0200Peak oxygen uptake (mlmin) -20 109 0741SAQ Physical Limitation 74 50 0420SAQ Angina Frequency 140 96 0260SAQ Angina Stability -42 -51 0851Quality of Life 003 003 0994Duke Treadmill Score 122 010 0104Complete Freedom from Angina 495 315 lt005

Compared with placebo PCI improved stress echo by 107 segment units (plt000001) with larger improvements in stress echo with lower levels of FFR and iFR (pinteraction lt000001)

Al-Lamee R et al Lancet 2018 391 31ndash40

22

Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis

80

23

Chan

ge in

PCr

ATP

dur

ing

stre

ss p

erce

nt

-50

-40

-30

-20

-10

0

10

20

30

gt70 StenosisWomen with Chest Pain

but normal Angio

ReferencePopulation

p lt 0025compared to normals

2 sd

Myocardial ischemia is frequent in subjects with signs and symptoms but no obstructive coronary diseaseThese are not ldquofalse positiverdquo stress tests

Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects

Buchal et al NEJM 2001

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 7: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

1615PC Bairey-MerzSlide

8

Bugiardini and Bairey Merz JAMA 2005293477-84

Paradox Women have a two-fold increase in ldquonormalrdquo Coronary arteries in the setting of ACS NSTEMI and STEMI

9

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Monet vs ManetMore womendie

More men receive treatment

Bairey Merz EHJ 2011

GuidelineImplementation ACS and the Sex Survival Gap

Novak et al Am J Medicine 2008121602

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrows(RED)

Novak et al Am J Medicine 2008121602

+

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrow (RED)

Persistent sex gap (BLUE)suggests more workstill neededto understand sex-specific pathophysiologyto improve outcomesfor women and men

Novak et al Am J Medicine 2008121602

+

14

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Anderson RD et al Circulation 2007115823-826

Prevalence of normal or non-obstructive coronary arteriescommon in women

Normal Coronaries

22

1V Non-Obstructive

CAD14

2V Non-Obstructive

CAD8

3V Non-Obstructive

CAD3

1V Obstructive CAD23

2V Obstructive CAD14

3VLM Obstructive

CAD16

VA CART 37674 male patients ndash47 non-obstructive or normal coronary arteries

Now common in men

17Crea Filippo Paolo G Camici and Cathleen Noel Bairey Merz Coronary microvascular dysfunction an update European heart journal (2013) eht513

Mechanisms of Myocardial Ischemia (including INOCA)

Coronary Vascular Resistance

bullEpicardial arteries normally

contribute lt10 of the

coronary vascular resistance

ndashhemodynamic significance when

gt70 of the lumen is obstructed

bullCoronary microvasculature

is responsible for gt70 of

the coronary resistance

under physiological

circumstances Gould KL et al Am J Cardiol 19743387ndash94 Camici P et al Heart Lung and Circ 20091819-27

wwwvhlabumnedu

Coronary Microvascular Dysfunction

Crea F et al Nature Reviews Cardiology 20151248ndash62

20

DES in Stable Angina ORBITA Trial

21

Change from Baseline PCI Sham P ValueExercise time (sec) 284 118 0200Peak oxygen uptake (mlmin) -20 109 0741SAQ Physical Limitation 74 50 0420SAQ Angina Frequency 140 96 0260SAQ Angina Stability -42 -51 0851Quality of Life 003 003 0994Duke Treadmill Score 122 010 0104Complete Freedom from Angina 495 315 lt005

Compared with placebo PCI improved stress echo by 107 segment units (plt000001) with larger improvements in stress echo with lower levels of FFR and iFR (pinteraction lt000001)

Al-Lamee R et al Lancet 2018 391 31ndash40

22

Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis

80

23

Chan

ge in

PCr

ATP

dur

ing

stre

ss p

erce

nt

-50

-40

-30

-20

-10

0

10

20

30

gt70 StenosisWomen with Chest Pain

but normal Angio

ReferencePopulation

p lt 0025compared to normals

2 sd

Myocardial ischemia is frequent in subjects with signs and symptoms but no obstructive coronary diseaseThese are not ldquofalse positiverdquo stress tests

Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects

Buchal et al NEJM 2001

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 8: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

9

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Monet vs ManetMore womendie

More men receive treatment

Bairey Merz EHJ 2011

GuidelineImplementation ACS and the Sex Survival Gap

Novak et al Am J Medicine 2008121602

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrows(RED)

Novak et al Am J Medicine 2008121602

+

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrow (RED)

Persistent sex gap (BLUE)suggests more workstill neededto understand sex-specific pathophysiologyto improve outcomesfor women and men

Novak et al Am J Medicine 2008121602

+

14

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Anderson RD et al Circulation 2007115823-826

Prevalence of normal or non-obstructive coronary arteriescommon in women

Normal Coronaries

22

1V Non-Obstructive

CAD14

2V Non-Obstructive

CAD8

3V Non-Obstructive

CAD3

1V Obstructive CAD23

2V Obstructive CAD14

3VLM Obstructive

CAD16

VA CART 37674 male patients ndash47 non-obstructive or normal coronary arteries

Now common in men

17Crea Filippo Paolo G Camici and Cathleen Noel Bairey Merz Coronary microvascular dysfunction an update European heart journal (2013) eht513

Mechanisms of Myocardial Ischemia (including INOCA)

Coronary Vascular Resistance

bullEpicardial arteries normally

contribute lt10 of the

coronary vascular resistance

ndashhemodynamic significance when

gt70 of the lumen is obstructed

bullCoronary microvasculature

is responsible for gt70 of

the coronary resistance

under physiological

circumstances Gould KL et al Am J Cardiol 19743387ndash94 Camici P et al Heart Lung and Circ 20091819-27

wwwvhlabumnedu

Coronary Microvascular Dysfunction

Crea F et al Nature Reviews Cardiology 20151248ndash62

20

DES in Stable Angina ORBITA Trial

21

Change from Baseline PCI Sham P ValueExercise time (sec) 284 118 0200Peak oxygen uptake (mlmin) -20 109 0741SAQ Physical Limitation 74 50 0420SAQ Angina Frequency 140 96 0260SAQ Angina Stability -42 -51 0851Quality of Life 003 003 0994Duke Treadmill Score 122 010 0104Complete Freedom from Angina 495 315 lt005

Compared with placebo PCI improved stress echo by 107 segment units (plt000001) with larger improvements in stress echo with lower levels of FFR and iFR (pinteraction lt000001)

Al-Lamee R et al Lancet 2018 391 31ndash40

22

Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis

80

23

Chan

ge in

PCr

ATP

dur

ing

stre

ss p

erce

nt

-50

-40

-30

-20

-10

0

10

20

30

gt70 StenosisWomen with Chest Pain

but normal Angio

ReferencePopulation

p lt 0025compared to normals

2 sd

Myocardial ischemia is frequent in subjects with signs and symptoms but no obstructive coronary diseaseThese are not ldquofalse positiverdquo stress tests

Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects

Buchal et al NEJM 2001

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 9: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

Monet vs ManetMore womendie

More men receive treatment

Bairey Merz EHJ 2011

GuidelineImplementation ACS and the Sex Survival Gap

Novak et al Am J Medicine 2008121602

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrows(RED)

Novak et al Am J Medicine 2008121602

+

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrow (RED)

Persistent sex gap (BLUE)suggests more workstill neededto understand sex-specific pathophysiologyto improve outcomesfor women and men

Novak et al Am J Medicine 2008121602

+

14

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Anderson RD et al Circulation 2007115823-826

Prevalence of normal or non-obstructive coronary arteriescommon in women

Normal Coronaries

22

1V Non-Obstructive

CAD14

2V Non-Obstructive

CAD8

3V Non-Obstructive

CAD3

1V Obstructive CAD23

2V Obstructive CAD14

3VLM Obstructive

CAD16

VA CART 37674 male patients ndash47 non-obstructive or normal coronary arteries

Now common in men

17Crea Filippo Paolo G Camici and Cathleen Noel Bairey Merz Coronary microvascular dysfunction an update European heart journal (2013) eht513

Mechanisms of Myocardial Ischemia (including INOCA)

Coronary Vascular Resistance

bullEpicardial arteries normally

contribute lt10 of the

coronary vascular resistance

ndashhemodynamic significance when

gt70 of the lumen is obstructed

bullCoronary microvasculature

is responsible for gt70 of

the coronary resistance

under physiological

circumstances Gould KL et al Am J Cardiol 19743387ndash94 Camici P et al Heart Lung and Circ 20091819-27

wwwvhlabumnedu

Coronary Microvascular Dysfunction

Crea F et al Nature Reviews Cardiology 20151248ndash62

20

DES in Stable Angina ORBITA Trial

21

Change from Baseline PCI Sham P ValueExercise time (sec) 284 118 0200Peak oxygen uptake (mlmin) -20 109 0741SAQ Physical Limitation 74 50 0420SAQ Angina Frequency 140 96 0260SAQ Angina Stability -42 -51 0851Quality of Life 003 003 0994Duke Treadmill Score 122 010 0104Complete Freedom from Angina 495 315 lt005

Compared with placebo PCI improved stress echo by 107 segment units (plt000001) with larger improvements in stress echo with lower levels of FFR and iFR (pinteraction lt000001)

Al-Lamee R et al Lancet 2018 391 31ndash40

22

Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis

80

23

Chan

ge in

PCr

ATP

dur

ing

stre

ss p

erce

nt

-50

-40

-30

-20

-10

0

10

20

30

gt70 StenosisWomen with Chest Pain

but normal Angio

ReferencePopulation

p lt 0025compared to normals

2 sd

Myocardial ischemia is frequent in subjects with signs and symptoms but no obstructive coronary diseaseThese are not ldquofalse positiverdquo stress tests

Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects

Buchal et al NEJM 2001

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 10: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

GuidelineImplementation ACS and the Sex Survival Gap

Novak et al Am J Medicine 2008121602

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrows(RED)

Novak et al Am J Medicine 2008121602

+

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrow (RED)

Persistent sex gap (BLUE)suggests more workstill neededto understand sex-specific pathophysiologyto improve outcomesfor women and men

Novak et al Am J Medicine 2008121602

+

14

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Anderson RD et al Circulation 2007115823-826

Prevalence of normal or non-obstructive coronary arteriescommon in women

Normal Coronaries

22

1V Non-Obstructive

CAD14

2V Non-Obstructive

CAD8

3V Non-Obstructive

CAD3

1V Obstructive CAD23

2V Obstructive CAD14

3VLM Obstructive

CAD16

VA CART 37674 male patients ndash47 non-obstructive or normal coronary arteries

Now common in men

17Crea Filippo Paolo G Camici and Cathleen Noel Bairey Merz Coronary microvascular dysfunction an update European heart journal (2013) eht513

Mechanisms of Myocardial Ischemia (including INOCA)

Coronary Vascular Resistance

bullEpicardial arteries normally

contribute lt10 of the

coronary vascular resistance

ndashhemodynamic significance when

gt70 of the lumen is obstructed

bullCoronary microvasculature

is responsible for gt70 of

the coronary resistance

under physiological

circumstances Gould KL et al Am J Cardiol 19743387ndash94 Camici P et al Heart Lung and Circ 20091819-27

wwwvhlabumnedu

Coronary Microvascular Dysfunction

Crea F et al Nature Reviews Cardiology 20151248ndash62

20

DES in Stable Angina ORBITA Trial

21

Change from Baseline PCI Sham P ValueExercise time (sec) 284 118 0200Peak oxygen uptake (mlmin) -20 109 0741SAQ Physical Limitation 74 50 0420SAQ Angina Frequency 140 96 0260SAQ Angina Stability -42 -51 0851Quality of Life 003 003 0994Duke Treadmill Score 122 010 0104Complete Freedom from Angina 495 315 lt005

Compared with placebo PCI improved stress echo by 107 segment units (plt000001) with larger improvements in stress echo with lower levels of FFR and iFR (pinteraction lt000001)

Al-Lamee R et al Lancet 2018 391 31ndash40

22

Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis

80

23

Chan

ge in

PCr

ATP

dur

ing

stre

ss p

erce

nt

-50

-40

-30

-20

-10

0

10

20

30

gt70 StenosisWomen with Chest Pain

but normal Angio

ReferencePopulation

p lt 0025compared to normals

2 sd

Myocardial ischemia is frequent in subjects with signs and symptoms but no obstructive coronary diseaseThese are not ldquofalse positiverdquo stress tests

Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects

Buchal et al NEJM 2001

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 11: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrows(RED)

Novak et al Am J Medicine 2008121602

+

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrow (RED)

Persistent sex gap (BLUE)suggests more workstill neededto understand sex-specific pathophysiologyto improve outcomesfor women and men

Novak et al Am J Medicine 2008121602

+

14

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Anderson RD et al Circulation 2007115823-826

Prevalence of normal or non-obstructive coronary arteriescommon in women

Normal Coronaries

22

1V Non-Obstructive

CAD14

2V Non-Obstructive

CAD8

3V Non-Obstructive

CAD3

1V Obstructive CAD23

2V Obstructive CAD14

3VLM Obstructive

CAD16

VA CART 37674 male patients ndash47 non-obstructive or normal coronary arteries

Now common in men

17Crea Filippo Paolo G Camici and Cathleen Noel Bairey Merz Coronary microvascular dysfunction an update European heart journal (2013) eht513

Mechanisms of Myocardial Ischemia (including INOCA)

Coronary Vascular Resistance

bullEpicardial arteries normally

contribute lt10 of the

coronary vascular resistance

ndashhemodynamic significance when

gt70 of the lumen is obstructed

bullCoronary microvasculature

is responsible for gt70 of

the coronary resistance

under physiological

circumstances Gould KL et al Am J Cardiol 19743387ndash94 Camici P et al Heart Lung and Circ 20091819-27

wwwvhlabumnedu

Coronary Microvascular Dysfunction

Crea F et al Nature Reviews Cardiology 20151248ndash62

20

DES in Stable Angina ORBITA Trial

21

Change from Baseline PCI Sham P ValueExercise time (sec) 284 118 0200Peak oxygen uptake (mlmin) -20 109 0741SAQ Physical Limitation 74 50 0420SAQ Angina Frequency 140 96 0260SAQ Angina Stability -42 -51 0851Quality of Life 003 003 0994Duke Treadmill Score 122 010 0104Complete Freedom from Angina 495 315 lt005

Compared with placebo PCI improved stress echo by 107 segment units (plt000001) with larger improvements in stress echo with lower levels of FFR and iFR (pinteraction lt000001)

Al-Lamee R et al Lancet 2018 391 31ndash40

22

Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis

80

23

Chan

ge in

PCr

ATP

dur

ing

stre

ss p

erce

nt

-50

-40

-30

-20

-10

0

10

20

30

gt70 StenosisWomen with Chest Pain

but normal Angio

ReferencePopulation

p lt 0025compared to normals

2 sd

Myocardial ischemia is frequent in subjects with signs and symptoms but no obstructive coronary diseaseThese are not ldquofalse positiverdquo stress tests

Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects

Buchal et al NEJM 2001

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 12: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

GuidelineImplementationACS and the Sex Survival GapFollowing guidelineimplementation mortality for womenimproves andthe sex gap narrow (RED)

Persistent sex gap (BLUE)suggests more workstill neededto understand sex-specific pathophysiologyto improve outcomesfor women and men

Novak et al Am J Medicine 2008121602

+

14

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Anderson RD et al Circulation 2007115823-826

Prevalence of normal or non-obstructive coronary arteriescommon in women

Normal Coronaries

22

1V Non-Obstructive

CAD14

2V Non-Obstructive

CAD8

3V Non-Obstructive

CAD3

1V Obstructive CAD23

2V Obstructive CAD14

3VLM Obstructive

CAD16

VA CART 37674 male patients ndash47 non-obstructive or normal coronary arteries

Now common in men

17Crea Filippo Paolo G Camici and Cathleen Noel Bairey Merz Coronary microvascular dysfunction an update European heart journal (2013) eht513

Mechanisms of Myocardial Ischemia (including INOCA)

Coronary Vascular Resistance

bullEpicardial arteries normally

contribute lt10 of the

coronary vascular resistance

ndashhemodynamic significance when

gt70 of the lumen is obstructed

bullCoronary microvasculature

is responsible for gt70 of

the coronary resistance

under physiological

circumstances Gould KL et al Am J Cardiol 19743387ndash94 Camici P et al Heart Lung and Circ 20091819-27

wwwvhlabumnedu

Coronary Microvascular Dysfunction

Crea F et al Nature Reviews Cardiology 20151248ndash62

20

DES in Stable Angina ORBITA Trial

21

Change from Baseline PCI Sham P ValueExercise time (sec) 284 118 0200Peak oxygen uptake (mlmin) -20 109 0741SAQ Physical Limitation 74 50 0420SAQ Angina Frequency 140 96 0260SAQ Angina Stability -42 -51 0851Quality of Life 003 003 0994Duke Treadmill Score 122 010 0104Complete Freedom from Angina 495 315 lt005

Compared with placebo PCI improved stress echo by 107 segment units (plt000001) with larger improvements in stress echo with lower levels of FFR and iFR (pinteraction lt000001)

Al-Lamee R et al Lancet 2018 391 31ndash40

22

Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis

80

23

Chan

ge in

PCr

ATP

dur

ing

stre

ss p

erce

nt

-50

-40

-30

-20

-10

0

10

20

30

gt70 StenosisWomen with Chest Pain

but normal Angio

ReferencePopulation

p lt 0025compared to normals

2 sd

Myocardial ischemia is frequent in subjects with signs and symptoms but no obstructive coronary diseaseThese are not ldquofalse positiverdquo stress tests

Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects

Buchal et al NEJM 2001

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 13: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

14

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Anderson RD et al Circulation 2007115823-826

Prevalence of normal or non-obstructive coronary arteriescommon in women

Normal Coronaries

22

1V Non-Obstructive

CAD14

2V Non-Obstructive

CAD8

3V Non-Obstructive

CAD3

1V Obstructive CAD23

2V Obstructive CAD14

3VLM Obstructive

CAD16

VA CART 37674 male patients ndash47 non-obstructive or normal coronary arteries

Now common in men

17Crea Filippo Paolo G Camici and Cathleen Noel Bairey Merz Coronary microvascular dysfunction an update European heart journal (2013) eht513

Mechanisms of Myocardial Ischemia (including INOCA)

Coronary Vascular Resistance

bullEpicardial arteries normally

contribute lt10 of the

coronary vascular resistance

ndashhemodynamic significance when

gt70 of the lumen is obstructed

bullCoronary microvasculature

is responsible for gt70 of

the coronary resistance

under physiological

circumstances Gould KL et al Am J Cardiol 19743387ndash94 Camici P et al Heart Lung and Circ 20091819-27

wwwvhlabumnedu

Coronary Microvascular Dysfunction

Crea F et al Nature Reviews Cardiology 20151248ndash62

20

DES in Stable Angina ORBITA Trial

21

Change from Baseline PCI Sham P ValueExercise time (sec) 284 118 0200Peak oxygen uptake (mlmin) -20 109 0741SAQ Physical Limitation 74 50 0420SAQ Angina Frequency 140 96 0260SAQ Angina Stability -42 -51 0851Quality of Life 003 003 0994Duke Treadmill Score 122 010 0104Complete Freedom from Angina 495 315 lt005

Compared with placebo PCI improved stress echo by 107 segment units (plt000001) with larger improvements in stress echo with lower levels of FFR and iFR (pinteraction lt000001)

Al-Lamee R et al Lancet 2018 391 31ndash40

22

Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis

80

23

Chan

ge in

PCr

ATP

dur

ing

stre

ss p

erce

nt

-50

-40

-30

-20

-10

0

10

20

30

gt70 StenosisWomen with Chest Pain

but normal Angio

ReferencePopulation

p lt 0025compared to normals

2 sd

Myocardial ischemia is frequent in subjects with signs and symptoms but no obstructive coronary diseaseThese are not ldquofalse positiverdquo stress tests

Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects

Buchal et al NEJM 2001

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 14: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

Anderson RD et al Circulation 2007115823-826

Prevalence of normal or non-obstructive coronary arteriescommon in women

Normal Coronaries

22

1V Non-Obstructive

CAD14

2V Non-Obstructive

CAD8

3V Non-Obstructive

CAD3

1V Obstructive CAD23

2V Obstructive CAD14

3VLM Obstructive

CAD16

VA CART 37674 male patients ndash47 non-obstructive or normal coronary arteries

Now common in men

17Crea Filippo Paolo G Camici and Cathleen Noel Bairey Merz Coronary microvascular dysfunction an update European heart journal (2013) eht513

Mechanisms of Myocardial Ischemia (including INOCA)

Coronary Vascular Resistance

bullEpicardial arteries normally

contribute lt10 of the

coronary vascular resistance

ndashhemodynamic significance when

gt70 of the lumen is obstructed

bullCoronary microvasculature

is responsible for gt70 of

the coronary resistance

under physiological

circumstances Gould KL et al Am J Cardiol 19743387ndash94 Camici P et al Heart Lung and Circ 20091819-27

wwwvhlabumnedu

Coronary Microvascular Dysfunction

Crea F et al Nature Reviews Cardiology 20151248ndash62

20

DES in Stable Angina ORBITA Trial

21

Change from Baseline PCI Sham P ValueExercise time (sec) 284 118 0200Peak oxygen uptake (mlmin) -20 109 0741SAQ Physical Limitation 74 50 0420SAQ Angina Frequency 140 96 0260SAQ Angina Stability -42 -51 0851Quality of Life 003 003 0994Duke Treadmill Score 122 010 0104Complete Freedom from Angina 495 315 lt005

Compared with placebo PCI improved stress echo by 107 segment units (plt000001) with larger improvements in stress echo with lower levels of FFR and iFR (pinteraction lt000001)

Al-Lamee R et al Lancet 2018 391 31ndash40

22

Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis

80

23

Chan

ge in

PCr

ATP

dur

ing

stre

ss p

erce

nt

-50

-40

-30

-20

-10

0

10

20

30

gt70 StenosisWomen with Chest Pain

but normal Angio

ReferencePopulation

p lt 0025compared to normals

2 sd

Myocardial ischemia is frequent in subjects with signs and symptoms but no obstructive coronary diseaseThese are not ldquofalse positiverdquo stress tests

Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects

Buchal et al NEJM 2001

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 15: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

Normal Coronaries

22

1V Non-Obstructive

CAD14

2V Non-Obstructive

CAD8

3V Non-Obstructive

CAD3

1V Obstructive CAD23

2V Obstructive CAD14

3VLM Obstructive

CAD16

VA CART 37674 male patients ndash47 non-obstructive or normal coronary arteries

Now common in men

17Crea Filippo Paolo G Camici and Cathleen Noel Bairey Merz Coronary microvascular dysfunction an update European heart journal (2013) eht513

Mechanisms of Myocardial Ischemia (including INOCA)

Coronary Vascular Resistance

bullEpicardial arteries normally

contribute lt10 of the

coronary vascular resistance

ndashhemodynamic significance when

gt70 of the lumen is obstructed

bullCoronary microvasculature

is responsible for gt70 of

the coronary resistance

under physiological

circumstances Gould KL et al Am J Cardiol 19743387ndash94 Camici P et al Heart Lung and Circ 20091819-27

wwwvhlabumnedu

Coronary Microvascular Dysfunction

Crea F et al Nature Reviews Cardiology 20151248ndash62

20

DES in Stable Angina ORBITA Trial

21

Change from Baseline PCI Sham P ValueExercise time (sec) 284 118 0200Peak oxygen uptake (mlmin) -20 109 0741SAQ Physical Limitation 74 50 0420SAQ Angina Frequency 140 96 0260SAQ Angina Stability -42 -51 0851Quality of Life 003 003 0994Duke Treadmill Score 122 010 0104Complete Freedom from Angina 495 315 lt005

Compared with placebo PCI improved stress echo by 107 segment units (plt000001) with larger improvements in stress echo with lower levels of FFR and iFR (pinteraction lt000001)

Al-Lamee R et al Lancet 2018 391 31ndash40

22

Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis

80

23

Chan

ge in

PCr

ATP

dur

ing

stre

ss p

erce

nt

-50

-40

-30

-20

-10

0

10

20

30

gt70 StenosisWomen with Chest Pain

but normal Angio

ReferencePopulation

p lt 0025compared to normals

2 sd

Myocardial ischemia is frequent in subjects with signs and symptoms but no obstructive coronary diseaseThese are not ldquofalse positiverdquo stress tests

Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects

Buchal et al NEJM 2001

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 16: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

17Crea Filippo Paolo G Camici and Cathleen Noel Bairey Merz Coronary microvascular dysfunction an update European heart journal (2013) eht513

Mechanisms of Myocardial Ischemia (including INOCA)

Coronary Vascular Resistance

bullEpicardial arteries normally

contribute lt10 of the

coronary vascular resistance

ndashhemodynamic significance when

gt70 of the lumen is obstructed

bullCoronary microvasculature

is responsible for gt70 of

the coronary resistance

under physiological

circumstances Gould KL et al Am J Cardiol 19743387ndash94 Camici P et al Heart Lung and Circ 20091819-27

wwwvhlabumnedu

Coronary Microvascular Dysfunction

Crea F et al Nature Reviews Cardiology 20151248ndash62

20

DES in Stable Angina ORBITA Trial

21

Change from Baseline PCI Sham P ValueExercise time (sec) 284 118 0200Peak oxygen uptake (mlmin) -20 109 0741SAQ Physical Limitation 74 50 0420SAQ Angina Frequency 140 96 0260SAQ Angina Stability -42 -51 0851Quality of Life 003 003 0994Duke Treadmill Score 122 010 0104Complete Freedom from Angina 495 315 lt005

Compared with placebo PCI improved stress echo by 107 segment units (plt000001) with larger improvements in stress echo with lower levels of FFR and iFR (pinteraction lt000001)

Al-Lamee R et al Lancet 2018 391 31ndash40

22

Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis

80

23

Chan

ge in

PCr

ATP

dur

ing

stre

ss p

erce

nt

-50

-40

-30

-20

-10

0

10

20

30

gt70 StenosisWomen with Chest Pain

but normal Angio

ReferencePopulation

p lt 0025compared to normals

2 sd

Myocardial ischemia is frequent in subjects with signs and symptoms but no obstructive coronary diseaseThese are not ldquofalse positiverdquo stress tests

Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects

Buchal et al NEJM 2001

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 17: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

Coronary Vascular Resistance

bullEpicardial arteries normally

contribute lt10 of the

coronary vascular resistance

ndashhemodynamic significance when

gt70 of the lumen is obstructed

bullCoronary microvasculature

is responsible for gt70 of

the coronary resistance

under physiological

circumstances Gould KL et al Am J Cardiol 19743387ndash94 Camici P et al Heart Lung and Circ 20091819-27

wwwvhlabumnedu

Coronary Microvascular Dysfunction

Crea F et al Nature Reviews Cardiology 20151248ndash62

20

DES in Stable Angina ORBITA Trial

21

Change from Baseline PCI Sham P ValueExercise time (sec) 284 118 0200Peak oxygen uptake (mlmin) -20 109 0741SAQ Physical Limitation 74 50 0420SAQ Angina Frequency 140 96 0260SAQ Angina Stability -42 -51 0851Quality of Life 003 003 0994Duke Treadmill Score 122 010 0104Complete Freedom from Angina 495 315 lt005

Compared with placebo PCI improved stress echo by 107 segment units (plt000001) with larger improvements in stress echo with lower levels of FFR and iFR (pinteraction lt000001)

Al-Lamee R et al Lancet 2018 391 31ndash40

22

Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis

80

23

Chan

ge in

PCr

ATP

dur

ing

stre

ss p

erce

nt

-50

-40

-30

-20

-10

0

10

20

30

gt70 StenosisWomen with Chest Pain

but normal Angio

ReferencePopulation

p lt 0025compared to normals

2 sd

Myocardial ischemia is frequent in subjects with signs and symptoms but no obstructive coronary diseaseThese are not ldquofalse positiverdquo stress tests

Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects

Buchal et al NEJM 2001

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 18: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

Coronary Microvascular Dysfunction

Crea F et al Nature Reviews Cardiology 20151248ndash62

20

DES in Stable Angina ORBITA Trial

21

Change from Baseline PCI Sham P ValueExercise time (sec) 284 118 0200Peak oxygen uptake (mlmin) -20 109 0741SAQ Physical Limitation 74 50 0420SAQ Angina Frequency 140 96 0260SAQ Angina Stability -42 -51 0851Quality of Life 003 003 0994Duke Treadmill Score 122 010 0104Complete Freedom from Angina 495 315 lt005

Compared with placebo PCI improved stress echo by 107 segment units (plt000001) with larger improvements in stress echo with lower levels of FFR and iFR (pinteraction lt000001)

Al-Lamee R et al Lancet 2018 391 31ndash40

22

Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis

80

23

Chan

ge in

PCr

ATP

dur

ing

stre

ss p

erce

nt

-50

-40

-30

-20

-10

0

10

20

30

gt70 StenosisWomen with Chest Pain

but normal Angio

ReferencePopulation

p lt 0025compared to normals

2 sd

Myocardial ischemia is frequent in subjects with signs and symptoms but no obstructive coronary diseaseThese are not ldquofalse positiverdquo stress tests

Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects

Buchal et al NEJM 2001

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 19: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

20

DES in Stable Angina ORBITA Trial

21

Change from Baseline PCI Sham P ValueExercise time (sec) 284 118 0200Peak oxygen uptake (mlmin) -20 109 0741SAQ Physical Limitation 74 50 0420SAQ Angina Frequency 140 96 0260SAQ Angina Stability -42 -51 0851Quality of Life 003 003 0994Duke Treadmill Score 122 010 0104Complete Freedom from Angina 495 315 lt005

Compared with placebo PCI improved stress echo by 107 segment units (plt000001) with larger improvements in stress echo with lower levels of FFR and iFR (pinteraction lt000001)

Al-Lamee R et al Lancet 2018 391 31ndash40

22

Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis

80

23

Chan

ge in

PCr

ATP

dur

ing

stre

ss p

erce

nt

-50

-40

-30

-20

-10

0

10

20

30

gt70 StenosisWomen with Chest Pain

but normal Angio

ReferencePopulation

p lt 0025compared to normals

2 sd

Myocardial ischemia is frequent in subjects with signs and symptoms but no obstructive coronary diseaseThese are not ldquofalse positiverdquo stress tests

Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects

Buchal et al NEJM 2001

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 20: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

DES in Stable Angina ORBITA Trial

21

Change from Baseline PCI Sham P ValueExercise time (sec) 284 118 0200Peak oxygen uptake (mlmin) -20 109 0741SAQ Physical Limitation 74 50 0420SAQ Angina Frequency 140 96 0260SAQ Angina Stability -42 -51 0851Quality of Life 003 003 0994Duke Treadmill Score 122 010 0104Complete Freedom from Angina 495 315 lt005

Compared with placebo PCI improved stress echo by 107 segment units (plt000001) with larger improvements in stress echo with lower levels of FFR and iFR (pinteraction lt000001)

Al-Lamee R et al Lancet 2018 391 31ndash40

22

Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis

80

23

Chan

ge in

PCr

ATP

dur

ing

stre

ss p

erce

nt

-50

-40

-30

-20

-10

0

10

20

30

gt70 StenosisWomen with Chest Pain

but normal Angio

ReferencePopulation

p lt 0025compared to normals

2 sd

Myocardial ischemia is frequent in subjects with signs and symptoms but no obstructive coronary diseaseThese are not ldquofalse positiverdquo stress tests

Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects

Buchal et al NEJM 2001

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 21: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

22

Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis

80

23

Chan

ge in

PCr

ATP

dur

ing

stre

ss p

erce

nt

-50

-40

-30

-20

-10

0

10

20

30

gt70 StenosisWomen with Chest Pain

but normal Angio

ReferencePopulation

p lt 0025compared to normals

2 sd

Myocardial ischemia is frequent in subjects with signs and symptoms but no obstructive coronary diseaseThese are not ldquofalse positiverdquo stress tests

Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects

Buchal et al NEJM 2001

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 22: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

23

Chan

ge in

PCr

ATP

dur

ing

stre

ss p

erce

nt

-50

-40

-30

-20

-10

0

10

20

30

gt70 StenosisWomen with Chest Pain

but normal Angio

ReferencePopulation

p lt 0025compared to normals

2 sd

Myocardial ischemia is frequent in subjects with signs and symptoms but no obstructive coronary diseaseThese are not ldquofalse positiverdquo stress tests

Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects

Buchal et al NEJM 2001

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 23: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

24

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 24: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

WISE CMD Randomized Pharmacologic PROBE TrialsTrial (n) Intervention Results

QWISE1 (n=78) quinipril CFR angina

FemHRT-WISE 2(n=35) ethinyl estradiol and norethindrone acetate

MRS angina

EWISE3 (n=41) eplenerone CFR angina

SWISE4 (n=23) sildenafil CFR angina

RWISE Pilot5 (n=20) ranolazine MPRI angina

RWISE6 (n=128) ranolazine MPRI angina

CFR = coronary flow reserve MRS = magnetic resonance spectrosopy myocardial perfusion reserve index WISE = Womenrsquos Ischemia Syndrome Evaluation 1 Pauley AHJ 2011 2 Bairey Merz AHJ 2010 3 BavryAHJ 2014 Denardo Clin Card 2011 5 Mehta JACC Imaging 6 Bairey Merz EHJ 2015

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 25: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

Randomized CRT Protocol Improves Angina Outcomes

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 26: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Carl Pepine MDNoel Bairey Merz MDEileen Handberg PhD

Rhonda Cooper-DeHoff PharmDJanet Wei MD

John Spertus MDBernard Chaitman MDWilliam Weintraub MD

4422 subjects with angina no obstructive CAD randomized to IMT (intensive statin and ACEARB) vs GMT (guideline directed risk factor management) for reduction of MACE (all-cause death non-fatal-MI -stroke or hospitalization for angina or HF)

Womenrsquos IschemiaSyndrome Evaluation

WISE

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 27: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial

Womenrsquos IschemiaSyndrome Evaluation

WISE

Intensive Medical therapy (IMT)

Guideline Medical Therapy (GMT)

Lipid Lowering Lowering

AtorvastatinIntolerant

Randomize

ACE InhibitorIntolerant

Maximally tolerated RAS Blockade

Lisinopril 10mg20mg40mg

PO QD 90Refills 3

Losartan25mg50mg100mg

PO QD 90Refills 3

Intensive Statin

Atorvastatin10mg20mg40mg80mg

PO QD 90Refills 3

Rosuvastatin 5mg10mg20mg40mg

PO QD 90Refills 3

Yes NoYes No

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 28: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 29: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart Truth and AHA Go Red Awarenessand Guidelines Campaigns

1997-2007

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 30: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 31: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
Page 32: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
Page 33: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
Page 34: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
Page 35: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
Page 36: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
Page 37: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
Page 38: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl
Total
Males
Females
Per 100000 Population
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
Page 39: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl
ampA
Page ampP

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
Page 40: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

380

400

420

440

460

480

500

520

79 80 85 90 95 00 04

Years

Death

s i

n T

ho

usan

ds

Males Females

0

NHLBI Heart TruthAHA WISE andGuideline Campaigns

1997-2007 43

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 41: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

Chart1

Males
Females
Years
Deaths in Thousands
496676
466361
506154
487194
487453
495286
444763
475482
452452
503139
440175
505661
410365
461152

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
79 79
80 80
49657 481104
491564 480988
494841 491291
487461 49071
85 85
477968 494949
472445 495989
473119 50085
453057 4831
90 90
443673 476809
441233 476675
454352 497858
4491 495675
95 95
450761 503646
447687 500725
443221 501741
445871 512904
00 00
432245 498863
433827 49369
427891 483372
04 04
Page 42: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

USCVTREND

ampA
Page ampP

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
CVD CVD Cardiovascular Disease Mortality Trends for Males and Females CVD CVD CVD CVD
Males Females United States 1979-2004 Males Females Males Females
79 500 469 79 497 466 79 497 466
80 510 490 80 506 487 80 506 487
81 500 484 497 481 85 487 495
82 495 484 492 481 90 445 475
83 498 494 495 491 95 452 503
84 491 493 487 491 00 439 505 adjusted
85 491 498 85 487 495 04 410 460 adjusted
86 481 498 478 495
87 475 499 472 496
88 476 504 473 501
89 456 486 453 483
90 448 478 90 445 475
91 447 479 444 477
92 444 479 441 477
93 457 500 454 498
94 452 498 449 496
95 455 505 95 452 503
96 453 506 451 504
97 450 503 448 501
98 446 504 Actual Mortality Adjusted Mortality 443 502
99 446 513 adjusted by 9-10 comparability ratio (09981) 445024 511929 446 513
00 440 506 440175 505661 439339 504700 00 440 506
01 432 499 432245 498863 431424 497915 432 499
Source Final mortality data NCHS 433827 493690 02 433003 492752 434 494
Numbers are in thousands 427891 483372 03 427078 482454 428 483
CVD including congenital CV disease 410365 461152 04 409585 460276 04 410 461
CVD CVD CVD CVD
White Males White Females Black Males Black Females - Since comparability ratio is so close to 100
79 445 418 48 46 it is not necessary to adjust As per TT 92606
80 452 435
81 444 430
82 439 430
83 441 438
84 434 437
85 433 440
86 423 440 50 52
87 417 440 50 52
88 417 443 50 54 White Males White Females Black Males Black Females
89 398 425 49 53 90 391 420 48 51
90 391 420 48 51 91 389 420 48 52
91 389 420 48 52 92 387 420 47 52
92 387 420 47 52 93 398 438 49 54
93 398 438 49 54 94 394 436 48 54
94 394 436 48 54 95 395 442 50 55
95 395 442 50 55 96 394 442 48 55
96 394 442 48 55 97 391 440 48 54
97 391 440 48 54 98 386 439 49 55
98 386 439 49 55 99 386 447 49 56
99 386 447 49 56 00 381 439 48 57
0 381 439 48 57
Cardiovascular Disease Mortality Trends by Sex and Race
United States 1990-2000
Page 43: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

USCVTREND

ampA
Page ampP
Males
Females
Years
Deaths in Thousands

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
Page 44: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

drwomencvcan

Males
Females
Years
Deaths in Thousands

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
Page 45: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

chdstrhypmor

White Males
White Females
Black Males
Black Females
Year
Deaths in Thousands
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
Page 46: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl
ampA
Page ampP
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
DR FOR WOMEN CV AND CANCER 1996(1940) DR FOR WOMEN CV AND CANCER 2004 CVD AND CANCER 2001
Whites Blacks White Females Black Females Total Males Females
Coronary Heart Disease 589 800 Coronary Heart Disease 1154 1486 CVD 3296 3914 2817
Stroke 229 392 Stroke 474 649 Cancer 1960 2437 1647
Breast Cancer 198 265 Lung Cancer 416 390
Lung Cancer 280 276 Breast Cancer 237 319
Age-Adjusted Death Rates for Coronary Heart Disease Stroke Breast Age-Adjusted Death Rates for Coronary Heart Disease Stroke and Lung Age-Adjusted Death Rates for Cardiovascular Disease and Cancer
and Lung Cancer for White and Black Females(1940) and Breast Cancer for White and Black Females United States 2001
United States 1996 Final Mortality United States 2004
Page 47: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl
ampA
Page ampP
Whites
Blacks
Per 100000 Population
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
Page 48: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl
White Females
Black Females
Per 100000 Population
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
Page 49: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl
Total
Males
Females
Per 100000 Population
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
Page 50: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl
ampA
Page ampP

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
OF HEART ATTACK amp STROKE DEATHS US 1979-91 of stroke deaths OF CHD DEATHS of hyp deaths
M CHD F CHD M STROKE F STROKE M STROKE F STROKE M CHD F CHD m f
79 307286 244079 551365 70439 9949 79 70439 9949 79 307286 244079 13786 1813
80 310774 254981 565755 69973 100252 80 69973 100252 80 310774 254981 13943 1869
81 303929 251229 555158 66429 97075 81 66429 97075 81 303929 251229 13822 17905
82 300820 251966 552786 63855 93855 82 63855 93855 82 30082 251966 1355 17828
83 297522 254970 552492 62847 92751 83 62847 92751 83 297522 25497 13803 17993
84 289461 251827 541288 61697 9263 84 61697 9263 84 289461 251827 13478 17863
85 286181 250624 536805 6078 9227 85 6078 9227 85 286181 250624 13507 17926
86 274184 246545 520729 59164 90479 86 59164 90479 86 274184 246545 13034 17955
87 267757 244381 512138 59061 90774 87 59061 90774 87 267757 244381 13382 17956
88 264505 245087 509592 59759 90758 88 59759 90758 88 264505 245087 13399 18295
89 257524 240497 498021 57321 8823 89 57321 8823 89 257524 240497 13648 18466
90 252597 236574 489171 56697 87391 90 56697 87391 90 252597 236574 13614 19004
91 249736 235702 485438 56714 86767 91 56714 86767 91 249736 235702 13947 19387
92 246913 233138 480051 92 56645 87124 92 246913 233138 1452 2009
93 250362 239701 490063 93 59048 9106 93 250362 239701 15306 21438
94 245350 236108 481458 94 60225 93081 94 24535 236108 15915 22287
95 244819 236468 481287 95 61563 96428 95 244819 236468 1666 23321
96 242036 234088 476124
97 237332 228769 466101
Page 51: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

1 An epidemic of death in

women

2 Low hanging fruit - gender

3 Critical investigation - sex

4 Results of our labor

5 Policy and our future

Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
Page 52: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

Is this optimal for women

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
Page 53: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

bull This slide set was adapted from the following 2004-6 ACCAHA guidelines

bull Cardiovascular Disease Prevention in Women 2004 2007 2010bull Management of Patients With ST-Elevation Myocardial Infarctionbull Management of Patients with Unstable Angina and Non-ST-Segment

Elevation Myocardial Infarctionbull Preventing Heart Attack and Death in Patients with Atherosclerotic

Cardiovascular Diseasebull Management of Patients with Chronic Stable Anginabull Update for Coronary Artery Bypass Graft Surgerybull Evaluation and Management of Chronic Heart Failure in the Adult

bull The full-text guidelines and executive summaries are also available on the

bull ACC and AHA websites at wwwaccorg and wwwamericanheartorg

Clinical Practice Guidelines

ACC=American College of Cardiology AHA=American Heart Association

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
Page 54: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

Under-representation of Women in Cardiovascular Clinical Trials

Melloni et al Circ Cardiovasc Qual Outcomes 2010

Remains low compared to disease prevalence and death rates - Largest gaps in CAD and HF due to phenotype inclusion criteria (eg obstructive CAD troponin and reduced ejection fraction)

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
Page 55: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

Monet or Manet

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37
Page 56: Ischemic Heart Disease in Women: Monet vs Manet (why women ...€¦ · Female-pattern Ischemic Heart Disease: (or why women have more adverse IHD outcomes) New female. majority. Yentl

DoD WARRIOR Trial

For more information subject referral or site participationmerzcshsorg310 423 9680

  • Ischemic Heart Disease in Women Monet vs Manet (why women have more adverse outcomes)
  • Financial conflicts of interests
  • Slide Number 3
  • Slide Number 4
  • Slide Number 5
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 7
  • Slide Number 8
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 10
  • Slide Number 11
  • Slide Number 12
  • Slide Number 13
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 15
  • VA CART 37674 male patients ndash 47 non-obstructive or normal coronary arteries
  • Mechanisms of Myocardial Ischemia (including INOCA)
  • Coronary Vascular Resistance
  • Coronary Microvascular Dysfunction
  • Slide Number 20
  • DES in Stable Angina ORBITA Trial
  • Mechanisms WISE-IVUS gt80 INOCA Subjects have Coronary Atherosclerosis
  • Mechanisms WISE-Magnetic Resonance Spectroscopy confirms Myocardial Ischemia over 70 of INOCA subjects
  • Slide Number 24
  • WISE CMD Randomized Pharmacologic PROBE Trials
  • Slide Number 26
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • WARRIOR Womenrsquos IschemiA TReatment Reduces Events In Non-ObstRuctive CAD Trial
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 30
  • Slide Number 31
  • Female-pattern Ischemic Heart Disease(or why women have more adverse IHD outcomes)
  • Slide Number 33
  • Slide Number 34
  • Under-representation of Women in Cardiovascular Clinical Trials
  • Monet or Manet
  • Slide Number 37